<DOC>
	<DOCNO>NCT01591460</DOCNO>
	<brief_summary>This open-label , multicenter , treatment response guide study evaluate sustain virological response safety triple combination therapy boceprevir , Pegasys ( peginterferon alfa-2a ) Copegus ( Ribavirin ) previously untreated patient genotype 1 chronic hepatitis C. In lead-in phase , patient receive dual combination therapy Pegasys Copegus 4 week . In follow triple combination therapy phase , 800 mg boceprevir , 180 mcg Pegasys 1000-1200 mg Copegus administer 24 , 32 44 week ; duration depend patient 's treatment response . The anticipated time study treatment 48 week .</brief_summary>
	<brief_title>A Triple Combination Therapy Study Boceprevir , Pegasys Copegus Previously Untreated Patients With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient &gt; /=18 year age Chronic liver disease consistent chronic hepatitis C , genotype 1 infection Serum HCV RNA quantifiable screening Patients previously treat pegylated interferon ( IFN ) , standard IFN , RBV direct act antiviral agent Compensated liver disease ( ChildPugh Grade A clinical classification patient cirrhosis : total score &lt; /=6 ) Negative urine blood pregnancy test ( woman childbearing potential ) Women ongoing pregnancy breast feed Male partner woman pregnant Therapy systemic antiviral , antineoplastic immunomodulatory treatment &lt; /=6 month prior first dose study drug Any investigational drug &lt; /=6 week prior first dose study drug History evidence decompensated liver disease History evidence medical condition associate chronic liver disease chronic hepatitis C Signs symptom hepatocellular carcinoma Coinfection HCV genotypes genotype 1 Coinfection hepatitis A , hepatitis B , and/or human immunodeficiency virus ( HIV ) Any patient increase risk anemia History severe psychiatric disease History immunologically mediate , chronic pulmonary , severe cardiac disease Current diseases adequately control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>